BACKGROUND: Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including photocoagulation and surgery, are being considered as options, but with limited success. Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein expressed in benign and malignant prostatic tissues, in some non-prostatic tissues, and in the endothelium of tumor-associated neovasculature of non-prostatic neoplasm. Some studies have suggested that the expression of PSMA is restricted to endothelium from tumor-associated neovasculature and might be stimulated by some tumor-secreted angiogenic factors. However, no previous study demonstrating PSMA expression in non-related tumor neovasculature, such as CNVM, has been performed to date. Furthermore, demonstration of PSMA expression in CNVM in AMD patients could reveal a novel target for antineovascular therapy. The purpose of this study was to evaluate the immunohistochemical expression of PSMA in CNVM from AMD. METHODS: Immunohistochemical analysis, with a standard avidin-biotin complex technique, was performed using an anti-PSMA mouse monoclonal antibody in 30 specimens of surgically excised CNVM from AMD patients. Antibody to an endothelial cell specific marker, factor VIII, was used to confirm the location of the endothelial cells. RESULTS: The angiogenic microvessels of the 30 cases demonstrated negative staining to PSMA while factor VIII was expressed in all cases. Seventy-five percent of the secretory-acinar epithelium of the prostatic hyperplasia specimen stained positive, confirming that the immunohistochemical technique was correctly performed. CONCLUSION: The absence of PSMA expression in non-tumoral neovasculature supports the theory, previously suggested, that endothelial cell PSMA expression may be stimulated by one or more tumor-secreted angiogenic factors. Angiogenesis is very important in neoplasia and the endothelial expression of PSMA in tumor-associated neovasculature may represent a target for antineovasculature-based therapy. The absence of PSMA expression in CNVM suggests that PSMA may not be a potential target for antineovasculature-based therapy.
BACKGROUND:Choroidal neovascular membrane (CNVM) is one of the leading causes of severe visual loss and is often associated with age-related macular degeneration (AMD). Various modalities of treatment, including photocoagulation and surgery, are being considered as options, but with limited success. Prostate-specific membrane antigen (PSMA) is a type II membrane glycoprotein expressed in benign and malignant prostatic tissues, in some non-prostatic tissues, and in the endothelium of tumor-associated neovasculature of non-prostatic neoplasm. Some studies have suggested that the expression of PSMA is restricted to endothelium from tumor-associated neovasculature and might be stimulated by some tumor-secreted angiogenic factors. However, no previous study demonstrating PSMA expression in non-related tumor neovasculature, such as CNVM, has been performed to date. Furthermore, demonstration of PSMA expression in CNVM in AMDpatients could reveal a novel target for antineovascular therapy. The purpose of this study was to evaluate the immunohistochemical expression of PSMA in CNVM from AMD. METHODS: Immunohistochemical analysis, with a standard avidin-biotin complex technique, was performed using an anti-PSMAmouse monoclonal antibody in 30 specimens of surgically excised CNVM from AMDpatients. Antibody to an endothelial cell specific marker, factor VIII, was used to confirm the location of the endothelial cells. RESULTS: The angiogenic microvessels of the 30 cases demonstrated negative staining to PSMA while factor VIII was expressed in all cases. Seventy-five percent of the secretory-acinar epithelium of the prostatic hyperplasia specimen stained positive, confirming that the immunohistochemical technique was correctly performed. CONCLUSION: The absence of PSMA expression in non-tumoral neovasculature supports the theory, previously suggested, that endothelial cell PSMA expression may be stimulated by one or more tumor-secreted angiogenic factors. Angiogenesis is very important in neoplasia and the endothelial expression of PSMA in tumor-associated neovasculature may represent a target for antineovasculature-based therapy. The absence of PSMA expression in CNVM suggests that PSMA may not be a potential target for antineovasculature-based therapy.
Authors: Jayakrishna Ambati; Balamurali K Ambati; Sonia H Yoo; Sean Ianchulev; Anthony P Adamis Journal: Surv Ophthalmol Date: 2003 May-Jun Impact factor: 6.048
Authors: D A L Maberley; H Hollands; J Chuo; G Tam; J Konkal; M Roesch; A Veselinovic; M Witzigmann; K Bassett Journal: Eye (Lond) Date: 2006-03 Impact factor: 3.775
Authors: Hans E Grossniklaus; Jun X Ling; Timothy M Wallace; Stefan Dithmar; Diane H Lawson; Cynthia Cohen; Victor M Elner; Susan G Elner; Paul Sternberg Journal: Mol Vis Date: 2002-04-21 Impact factor: 2.367
Authors: J T Pinto; B P Suffoletto; T M Berzin; C H Qiao; S Lin; W P Tong; F May; B Mukherjee; W D Heston Journal: Clin Cancer Res Date: 1996-09 Impact factor: 12.531
Authors: Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-15 Impact factor: 9.236
Authors: Birthe Heitkötter; Marcel Trautmann; Inga Grünewald; Martin Bögemann; Kambiz Rahbar; Heidrun Gevensleben; Eva Wardelmann; Wolfgang Hartmann; Konrad Steinestel; Sebastian Huss Journal: Oncotarget Date: 2017-01-17
Authors: Birthe Heitkötter; Konrad Steinestel; Marcel Trautmann; Inga Grünewald; Peter Barth; Heidrun Gevensleben; Martin Bögemann; Eva Wardelmann; Wolfgang Hartmann; Kambiz Rahbar; Sebastian Huss Journal: Oncotarget Date: 2018-01-04
Authors: Lars Henning Schmidt; Birthe Heitkötter; Arik B Schulze; Christoph Schliemann; Konrad Steinestel; Marcel Trautmann; Alessandro Marra; Ludger Hillejan; Michael Mohr; Georg Evers; Eva Wardelmann; Kambiz Rahbar; Dennis Görlich; Georg Lenz; Wolfgang E Berdel; Wolfgang Hartmann; Rainer Wiewrodt; Sebastian Huss Journal: PLoS One Date: 2017-10-27 Impact factor: 3.240
Authors: Katharina Stock; Konrad Steinestel; Rebekka Wiesch; Jan-Henrik Mikesch; Anna Hansmeier; Marcel Trautmann; Nora Beller; Jan Rehkämper; Eva Wardelmann; Birthe Heitkötter; Wolfgang Hartmann; Jan Sperveslage; Sebastian Huss Journal: Biomed Res Int Date: 2017-10-25 Impact factor: 3.411